This article is more than 5 years old. Information may no longer be current.

AqueSys raises $43.6 million in Series D financing

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

New and existing investors have enabled AqueSys to secure $43.6 million in Series D financing, according to a press release.

“AqueSys is very pleased to raise this significant round of financing with a premier group of venture capital and private equity partners who share our vision to significantly improve the glaucoma treatment paradigm through highly effective yet minimally invasive technology,” Ron Bache, AqueSys president and CEO, said in the release.

Existing investors include Accuitive Medical Ventures, The Carlyle Group, Longitude Capital, Rho Ventures and SV Life Sciences, according to the release.

AqueSys is developing Xen Gel Stent technology for treating glaucoma and has finished enrollment in its first U.S. Food and Drug Administration approved investigational device exemption study and begun enrollment in its second study using the technology, according to the release.